Registry for Prostate Cancer Focal Therapy
Prospective Database / Registry of Focal Therapy for Prostate Cancer
About This Trial
- This study is looking at how safe and effective targeted treatments are for prostate cancer.
- Instead of treating or removing the entire prostate gland, these procedures aim to destroy only the cancerous areas to help patients avoid common side effects like bladder and sexual problems.
- The study is for men who are receiving or have received one of these targeted treatments at Queen Mary Hospital.
- Before joining, you should know that this is an observational study that collects and tracks your health records and recovery over time, so it will not change your planned care or give you an experimental medicine.
More Information
- Whole gland therapy (radical prostatectomy and radiotherapy) has been the conventional treatment for localized prostate cancer, but randomized controlled trials have not demonstrated survival benefits compared with watchful waiting or active surveillance.
- Whole gland therapy is also associated with significant long-term sequelae including urinary incontinence, erectile dysfunction, irradiation cystitis, and proctitis.
- Focal therapy has emerged as an alternative treatment modality, yet more data are needed to ensure its safety and efficacy.
- This is a prospective database/registry study designed to record all pre-operative, intra-operative, and post-operative parameters for patients undergoing focal therapies for prostate cancer, including but not limited to cryotherapy, high-intensity focused ultrasound (HIFU), focal laser therapy (FLA), irreversible electroporation (IRE), targeted microwave ablation (TMA).
- All patients who have undergone focal therapy at the Department of Surgery, Queen Mary Hospital for prostate cancer will be invited to participate, except those incapable of providing written informed consent.
- The primary outcome is the surgical outcomes (complications and effectiveness) of focal therapies.
- Secondary outcomes include identification of risk factors for treatment-related complications, provision of a readily available dataset for subsequent research, and identification of the best treatment allocation for prostate cancer patients.
- An estimated 200 patients will be included, with data collection from study start until 31 March 2030.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This study is looking at how safe and effective targeted treatments are for prostate cancer.
Study Details
- Start Date: October 31, 2025
- Lead Sponsor: The University of Hong Kong
Full Eligibility Criteria
Inclusion Criteria
- Patients who have undergone focal therapies for prostate cancer at the Department of Surgery, Queen Mary Hospital
- Includes but not limited to: cryotherapy, high-intensity focused ultrasound (HIFU), focal laser therapy (FLA), and irreversible electroporation (IRE)
- Willing and able to provide written informed consent
Exclusion Criteria
- Patients who are incapable to provide written informed consent.
Treatments
- Procedure: Focal Therapy for Prostate Cancer